Brachytherapy, or interstitial radiation, is a successful approach for treatment of prostate cancer. In brachytherapy, a large number (50-100) of rice grain-sized seeds of Pd-103 or Iodine-125 are inserted into the prostate gland for delivering local radiation and eradicating cancerous cells. Outcome data for prostate brachytherapy from numerous centers, out to eight years, demonstrates that this technique results in high negative biopsy rates and, in a large majority of cases, no persistence of the disease. The current proposal addresses the development of linear interstitial radiation therapy sources produced by the ion implantation technology. Radionuclide ion implantation creates a sealed source directly on thin gauge platinum """"""""micro-wires"""""""". These new brachytherapy sources offer the following advantages: 1. linear geometry, with uniform activity for controllable 3-dimensional dose distribution; 2. adjustable length source (can be cut to any length); 3. excellent pushability for quick release through the needle; 4. thinner profile for ease of insertion and minimum gland displacement; 5. reduce procedure time for source placement and thus, less exposure to physicians and other personnel; 6. minimum chance of migration and dislodgment; 7. vastly expanded radionuclide selection for patient specific dose and dose distribution requirements; 8. reliable, reproducible, automated manufacturing; 9. much reduced cost.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA078005-01
Application #
2645333
Study Section
Special Emphasis Panel (ZRG2-SSS-1 (02))
Program Officer
Stone, Helen B
Project Start
1998-03-04
Project End
1998-08-31
Budget Start
1998-03-04
Budget End
1998-08-31
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Radiomed Corporation
Department
Type
DUNS #
City
Tyngsboro
State
MA
Country
United States
Zip Code
01879